Disulfiram in Glioma: Literature Review of Drug Repurposing

Overview

Journal Front Pharmacol

Date 2022 Sep 12

PMID 36091753

Authors

Shiyu Zhong

Shengyu Liu

Xin Shi

Xudong Zhang

Kunhang Li

Guojun Liu

Lishuai Li

Shanwei Tao

Bowen Zheng

Weichen Sheng

Ziyin Ye

Qichen Xing

Qingqing Zhai

Lijie Ren

Ying Wu

Yijun Bao

Affiliations

Soon will be listed here.

Abstract

Gliomas are the most common malignant brain tumors. High-grade gliomas, represented by glioblastoma multiforme (GBM), have a poor prognosis and are prone to recurrence. The standard treatment strategy is tumor removal combined with radiotherapy and chemotherapy, such as temozolomide (TMZ). However, even after conventional treatment, they still have a high recurrence rate, resulting in an increasing demand for effective anti-glioma drugs. Drug repurposing is a method of reusing drugs that have already been widely approved for new indication. It has the advantages of reduced research cost, safety, and increased efficiency. Disulfiram (DSF), originally approved for alcohol dependence, has been repurposed for adjuvant chemotherapy in glioma. This article reviews the drug repurposing method and the progress of research on disulfiram reuse for glioma treatment.

Citing Articles

Exploring the role of Disulfidptosis in glioma progression: insights into tumor heterogeneity and therapeutic potential through single-cell RNA sequencing.

Fan X, Chen M Discov Oncol. 2024; 15(1):829.

PMID: 39714742 PMC: 11666858. DOI: 10.1007/s12672-024-01685-8.

Diethyldithiocarbamate-ferrous oxide nanoparticles inhibit human and mouse glioblastoma stemness: aldehyde dehydrogenase 1A1 suppression and ferroptosis induction.

Abu-Serie M, Osuka S, Heikal L, Teleb M, Barakat A, Dudeja V Front Pharmacol. 2024; 15:1363511.

PMID: 38720782 PMC: 11076782. DOI: 10.3389/fphar.2024.1363511.

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.

Liu J, Yang F, Hu J, Zhang X CNS Neurosci Ther. 2024; 30(5):e14715.

PMID: 38708806 PMC: 11071172. DOI: 10.1111/cns.14715.

References

Halatsch M, Kast R, Karpel-Massler G, Mayer B, Zolk O, Schmitz B . A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neurooncol Adv. 2021; 3(1):vdab075. PMC: 8349180. DOI: 10.1093/noajnl/vdab075. View

Karamanakos P, Trafalis D, Papachristou D, Panteli E, Papavasilopoulou M, Karatzas A . Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme - A propos of a case. J BUON. 2017; 22(5):1227-1232. View

Wu H, Huang J, Zhong Y, Huang Q . DrugSig: A resource for computational drug repositioning utilizing gene expression signatures. PLoS One. 2017; 12(5):e0177743. PMC: 5451001. DOI: 10.1371/journal.pone.0177743. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Swetha K, Sharma S, Chowdhury R, Roy A . Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy. Pharmacol Rep. 2020; 72(6):1749-1765. DOI: 10.1007/s43440-020-00122-1. View

Abidin I, Rezoagli E, Simonassi-Paiva B, Fehrenbach G, Masterson K, Pogue R . A Bilayer Vaginal Tablet for the Localized Delivery of Disulfiram and 5-Fluorouracil to the Cervix. Pharmaceutics. 2020; 12(12). PMC: 7762309. DOI: 10.3390/pharmaceutics12121185. View

Mutter N, Stupp R . Temozolomide: a milestone in neuro-oncology and beyond?. Expert Rev Anticancer Ther. 2006; 6(8):1187-204. DOI: 10.1586/14737140.6.8.1187. View

Seliger C, Hau P . Drug Repurposing of Metabolic Agents in Malignant Glioma. Int J Mol Sci. 2018; 19(9). PMC: 6164672. DOI: 10.3390/ijms19092768. View

Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D . Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules. 2021; 11(11). PMC: 8615869. DOI: 10.3390/biom11111561. View

10.

Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M . Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012; 3(10):1112-23. PMC: 3717961. DOI: 10.18632/oncotarget.604. View

11.

Huang J, Chaudhary R, Cohen A, Fink K, Goldlust S, Boockvar J . A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 2019; 142(3):537-544. DOI: 10.1007/s11060-019-03125-y. View

12.

Gottlieb A, Stein G, Ruppin E, Sharan R . PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol. 2011; 7:496. PMC: 3159979. DOI: 10.1038/msb.2011.26. View

13.

Rappa F, Cappello F, Halatsch M, Scheuerle A, Kast R . Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells. Biochimie. 2012; 95(4):782-6. DOI: 10.1016/j.biochi.2012.11.007. View

14.

Cvek B . Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). Drug Discov Today. 2011; 17(9-10):409-12. DOI: 10.1016/j.drudis.2011.12.010. View

15.

Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A . DrugR+: A comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Comput Biol Med. 2019; 109:254-262. DOI: 10.1016/j.compbiomed.2019.05.006. View

16.

Shirley D, Sharma I, Warren C, Moonah S . Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent. Front Cell Infect Microbiol. 2021; 11:633194. PMC: 7991622. DOI: 10.3389/fcimb.2021.633194. View

17.

Brown A, Patel C . MeSHDD: Literature-based drug-drug similarity for drug repositioning. J Am Med Inform Assoc. 2016; 24(3):614-618. PMC: 5391732. DOI: 10.1093/jamia/ocw142. View

18.

Tesson M, Anselmi G, Bell C, Mairs R . Cell cycle specific radiosensitisation by the disulfiram and copper complex. Oncotarget. 2017; 8(39):65900-65916. PMC: 5630381. DOI: 10.18632/oncotarget.19539. View

19.

Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen L, Bork P . STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res. 2011; 40(Database issue):D876-80. PMC: 3245073. DOI: 10.1093/nar/gkr1011. View

20.

Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y . Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013; 8(4):e60618. PMC: 3617101. DOI: 10.1371/journal.pone.0060618. View